Please login to Zacks.com or register to post a comment.
They're hand-picked from the list of Zacks Rank #1 Strong Buys. Our experts predict that their prices will jump the soonest.
Today, you can see them free.
| No Recent Quote currently available |
|
My Portfolio Tracker One of the most important steps you can take today is to set up your portfolio tracker on Zacks.com. Once you do, you'll be notified of major events affecting your stocks and/or funds with daily email alerts. Set yours up today. |
Zacks Rank Home - Evaluate your stocks and use the Zacks Rank to eliminate the losers and keep the winners.
Mutual Fund Rank Home - Evaluate your funds with the Mutual Fund Rank for both your personal and retirement funds.
Stock/Mutual Fund Screening - Find better stocks and mutual funds. The ones most likely to beat the market and provide a positive return.
My Portfolio - Track your Portfolio and find out where your stocks/mutual funds stack up with the Zacks Rank.
| Company Name | Symbol | %Change |
|---|---|---|
| STAAR SURGIC | STAA | 10.98% |
| DTS INC | DTSI | 6.89% |
| ANIKA THERAP | ANIK | 6.04% |
| LUMOS NETWOR | LMOS | 5.70% |
| INSTEEL IND | IIIN | 5.28% |
Please login to Zacks.com or register to post a comment.
Resources
Client Support
Zacks Research is Reported On:
Zacks Investment Research
is an A+ Rated BBB
Accredited Business.
Copyright 2013 Zacks Investment Research
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1986 it has nearly tripled the S&P 500 with an average gain of +26% per year. These returns cover a period from 1986-2011 and were examined and attested by Baker Tilly, an independent accounting firm.
Visit performance for information about the performance numbers displayed above.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This page is temporarily not available. Please check later as it should be available shortly. If you have any questions, please email customer support at support@zacks.com or call 800-767-3771 ext. 9339.
In an effort to provide investors an alternative way to execute their trading, NYSE Euronext (NYX - Analyst Report) was granted permission by the U.S. Securities and Exchange Commission (“SEC”) to introduce its innovative Retail Liquidity Program (“RLP”). NYSE plans to kick start the first-of-its-kind program early next month.
Despite the dissatisfaction expressed by many brokers in the industry, SEC believes that RLP will promote healthy competition across trading platforms. It is also in line with the regulatory norms and is designed to benefit investors by offering them a competitive price.
RLP will allow shares to be traded separately even before it is available for trading on the New York Stock Exchange (“NYSE”) floor. This technology would allow sufficient cost savings and ensure better pricing with respect to retail equity trading for NYSE and NYSE MKT listed and NASDAQ UTP-traded equity securities.
A couple of new market participants would be provided on NYSE and NYSE MKT. Firstly, the RLPs are slated to provide price improvements, even if its more or less by a penny, combined with services delivered towards Retail Member Organizations that are responsible for submitting Retail Orders to the Exchange.
With the introduction of RLP, NYSE will become the only U.S. bourse to offer such technology, comfortably outpacing its closest peers like Nasdaq OMX Group Inc. (NDAQ - Analyst Report) and CME Group Inc. (CME - Analyst Report).
NYSE continues to maintain a leadership position by developing a market model in response to the emerging trends and technological advancements in the trading environment. The company has initiated several undertakings by expanding the suite of technology service offering to its clients and aiding in a strategic shift of companies from other exchanges to the NYSE trading platform and also provided transparent pricing, useful trading information and the ability to develop cutting-edge products in the future.
NYSE currently retains a Zacks #3 Rank, which translates into a short-term Hold rating. However, we maintain a long-term Underperform rating on the shares of the company.
Get the full Analyst Report on CME - FREE
Get the full Analyst Report on NDAQ - FREE
Get the full Analyst Report on NYX - FREE